Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III …
QJ Li, MK He, HW Chen, WQ Fang, YM Zhou… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE In a previous phase II trial, hepatic arterial infusion chemotherapy (HAIC) with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment …
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment …
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE …
E Dhondt, B Lambert, L Hermie, L Huyck… - Radiology, 2022 - pubs.rsna.org
Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A Vogel, A Cervantes, I Chau, B Daniele… - Annals of …, 2018 - annalsofoncology.org
The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …
20 years and is expected to increase until 2030 in some countries including the United …
Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases
This guidance provides a data-supported approach to the diagnosis, staging, and treatment
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …
Epidemiology and management of hepatocellular carcinoma
L Kulik, HB El-Serag - Gastroenterology, 2019 - Elsevier
The major risk factors for hepatocellular carcinoma (HCC) in contemporary clinical practice
are becoming increasingly related to sustained virological response after hepatitis C …
are becoming increasingly related to sustained virological response after hepatitis C …